Evidence map›Paper›PMID 20127274›Full record

ArticleClinical & experimental metastasis2010

Id2 deficiency promotes metastasis in a mouse model of ocular cancer.

Olga A Agapova, Erica Person, J William Harbour

Abstract read
In one paragraph

Article in Clinical & experimental metastasis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Olga A AgapovaDepartment of Ophthalmology & Visual Sciences and Siteman Cancer Center, Washington University School of Medicine, Campus Box 8096, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
Erica Person
J William Harbour
Washington University in St. Louis · US

Funding

WASHINGTON UNIVERSITY CENTER VISION RESEARCHP30EY002687 · NEI · WASHINGTON UNIVERSITY · PI Philip Andrew Ruzycki · 1985 to 2026
$18.4M
MOLECULAR PREDICTIVE TESTING IN OCULAR MELANOMAR01CA125970 · NCI · WASHINGTON UNIVERSITY · PI CORREA, ZELIA MARIA, HARBOUR, JAMES WILLIAM · 2006 to 2021
$4.9M
THE ROLE OF RB IN THE RETINA &OTHER TISSUESR01EY013169 · NEI · WASHINGTON UNIVERSITY · PI HARBOUR, JAMES WILLIAM · 2000 to 2009
$3.0M
NCI NIH HHS R01 CA125970NEI NIH HHS P30 EY002687NEI NIH HHS P30 EY 02687NEI NIH HHS R01 EY013169NEI NIH HHS R01 EY1316905
6 · The paper itself

Abstract

The inhibitor of DNA binding 2 (Id2) basic helix-loop-helix protein interacts genetically and physically with the pocket proteins (Rb, p107 and p130) and has been implicated as an oncogene. In other studies, however, Id2 has been shown to function as a tumor suppressor. Here, we studied the role of Id2 in a well characterized model of ocular cancer in which the three pocket proteins are inactivated by generating mice lacking one or both Id2 alleles. Id2 deficiency had no impact on tumorigenesis in the eye. Unexpectedly, however, Id2 loss significantly increased the rate of metastasis. Liver metastases in Id2 heterozygotes demonstrated significant decrease of Id2 expression and loss of the remaining Id2 allele, strongly suggesting that Id2 inactivation specifically was required for metastasis in this model. These findings provide new insights into the role of Id2 in metastasis.

Indexed as

Disease Models, AnimalAllelesAnimalsBase SequenceDNA PrimersEye NeoplasmsFemaleInhibitor of Differentiation Protein 2Liver NeoplasmsMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicNeoplasm MetastasisDNA PrimersIdb2 protein, mouseInhibitor of Differentiation Protein 2

Identifiers

PMID20127274
PMCPMC4467556
OpenAlexW2066095096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.